Molecular classification and genetic pathways in hyperplastic polyposis syndrome

Luis Carvajal-Carmona, K. M. Howarth, M. Lockett, G. M. Polanco-Echeverry, E. Volikos, M. Gorman, E. Barclay, L. Martin, A. M. Jones, B. Saunders, T. Guenther, A. Donaldson, J. Paterson, I. Frayling, M. R. Novelli, R. Phillips, H. J W Thomas, A. Silver, W. Atkin, I. P M Tomlinson

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Hyperplastic Polyposis (HPPS) is a poorly characterized syndrome that increases colorectal cancer (CRC) risk. We aimed to provide a molecular classification of HPPS. We obtained 282 tumours from 32 putative HPPS patients with ≥10 hyperplastic polyps (HPs); some patients also had adenomas and CRCs. We found no good evidence of microsatellite instability (MSI) in our samples. The epithelium of HPs was monoclonal. Somatic BRAF mutations occurred in two-thirds of our patients' HPs, and KRAS2 mutations in 10%; both mutations were more common in younger cases. The respective mutation frequencies in a set of 'sporadic' HPs were 18% and 10%. Importantly, the putative HPPS patients generally fell into two readily defined groups, one set whose polyps had BRAF mutations, and another set whose polyps had KRAS2 mutations. The most plausible explanation for this observation is that there exist different forms of inherited predisposition to HPPS, and that these determine whether polyps follow a BRAF or KRAS2 pathway. Most adenomas and CRCs from our putative HPPS patients had 'classical' morphology and few of these lesions had BRAF or KRAS2 mutations. These findings suggest that tumourigenesis in HPPS does not necessarily follow the 'serrated' pathway. Although current definitions of HPPS are sub-optimal, we suggest that diagnosis could benefit from molecular analysis. Specifically, testing BRAF and KRAS2 mutations, and perhaps MSI, in multiple polyps could help to distinguish HPPS from sporadic HPs. We propose a specific model which would have diagnosed five more of our cases as HPPS compared with the WHO clinical criteria.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalJournal of Pathology
Volume212
Issue number4
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Polyps
Molecular Biology
Mutation
Microsatellite Instability
Adenoma
Mutation Rate
Colorectal Neoplasms
Epithelium

Keywords

  • Colorectal tumourigenesis
  • Genetic pathways
  • Hyperplastic polyps

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Carvajal-Carmona, L., Howarth, K. M., Lockett, M., Polanco-Echeverry, G. M., Volikos, E., Gorman, M., ... Tomlinson, I. P. M. (2007). Molecular classification and genetic pathways in hyperplastic polyposis syndrome. Journal of Pathology, 212(4), 378-385. https://doi.org/10.1002/path.2187

Molecular classification and genetic pathways in hyperplastic polyposis syndrome. / Carvajal-Carmona, Luis; Howarth, K. M.; Lockett, M.; Polanco-Echeverry, G. M.; Volikos, E.; Gorman, M.; Barclay, E.; Martin, L.; Jones, A. M.; Saunders, B.; Guenther, T.; Donaldson, A.; Paterson, J.; Frayling, I.; Novelli, M. R.; Phillips, R.; Thomas, H. J W; Silver, A.; Atkin, W.; Tomlinson, I. P M.

In: Journal of Pathology, Vol. 212, No. 4, 08.2007, p. 378-385.

Research output: Contribution to journalArticle

Carvajal-Carmona, L, Howarth, KM, Lockett, M, Polanco-Echeverry, GM, Volikos, E, Gorman, M, Barclay, E, Martin, L, Jones, AM, Saunders, B, Guenther, T, Donaldson, A, Paterson, J, Frayling, I, Novelli, MR, Phillips, R, Thomas, HJW, Silver, A, Atkin, W & Tomlinson, IPM 2007, 'Molecular classification and genetic pathways in hyperplastic polyposis syndrome', Journal of Pathology, vol. 212, no. 4, pp. 378-385. https://doi.org/10.1002/path.2187
Carvajal-Carmona L, Howarth KM, Lockett M, Polanco-Echeverry GM, Volikos E, Gorman M et al. Molecular classification and genetic pathways in hyperplastic polyposis syndrome. Journal of Pathology. 2007 Aug;212(4):378-385. https://doi.org/10.1002/path.2187
Carvajal-Carmona, Luis ; Howarth, K. M. ; Lockett, M. ; Polanco-Echeverry, G. M. ; Volikos, E. ; Gorman, M. ; Barclay, E. ; Martin, L. ; Jones, A. M. ; Saunders, B. ; Guenther, T. ; Donaldson, A. ; Paterson, J. ; Frayling, I. ; Novelli, M. R. ; Phillips, R. ; Thomas, H. J W ; Silver, A. ; Atkin, W. ; Tomlinson, I. P M. / Molecular classification and genetic pathways in hyperplastic polyposis syndrome. In: Journal of Pathology. 2007 ; Vol. 212, No. 4. pp. 378-385.
@article{ad7601e5e059421c8e694e3b634bc31f,
title = "Molecular classification and genetic pathways in hyperplastic polyposis syndrome",
abstract = "Hyperplastic Polyposis (HPPS) is a poorly characterized syndrome that increases colorectal cancer (CRC) risk. We aimed to provide a molecular classification of HPPS. We obtained 282 tumours from 32 putative HPPS patients with ≥10 hyperplastic polyps (HPs); some patients also had adenomas and CRCs. We found no good evidence of microsatellite instability (MSI) in our samples. The epithelium of HPs was monoclonal. Somatic BRAF mutations occurred in two-thirds of our patients' HPs, and KRAS2 mutations in 10{\%}; both mutations were more common in younger cases. The respective mutation frequencies in a set of 'sporadic' HPs were 18{\%} and 10{\%}. Importantly, the putative HPPS patients generally fell into two readily defined groups, one set whose polyps had BRAF mutations, and another set whose polyps had KRAS2 mutations. The most plausible explanation for this observation is that there exist different forms of inherited predisposition to HPPS, and that these determine whether polyps follow a BRAF or KRAS2 pathway. Most adenomas and CRCs from our putative HPPS patients had 'classical' morphology and few of these lesions had BRAF or KRAS2 mutations. These findings suggest that tumourigenesis in HPPS does not necessarily follow the 'serrated' pathway. Although current definitions of HPPS are sub-optimal, we suggest that diagnosis could benefit from molecular analysis. Specifically, testing BRAF and KRAS2 mutations, and perhaps MSI, in multiple polyps could help to distinguish HPPS from sporadic HPs. We propose a specific model which would have diagnosed five more of our cases as HPPS compared with the WHO clinical criteria.",
keywords = "Colorectal tumourigenesis, Genetic pathways, Hyperplastic polyps",
author = "Luis Carvajal-Carmona and Howarth, {K. M.} and M. Lockett and Polanco-Echeverry, {G. M.} and E. Volikos and M. Gorman and E. Barclay and L. Martin and Jones, {A. M.} and B. Saunders and T. Guenther and A. Donaldson and J. Paterson and I. Frayling and Novelli, {M. R.} and R. Phillips and Thomas, {H. J W} and A. Silver and W. Atkin and Tomlinson, {I. P M}",
year = "2007",
month = "8",
doi = "10.1002/path.2187",
language = "English (US)",
volume = "212",
pages = "378--385",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Molecular classification and genetic pathways in hyperplastic polyposis syndrome

AU - Carvajal-Carmona, Luis

AU - Howarth, K. M.

AU - Lockett, M.

AU - Polanco-Echeverry, G. M.

AU - Volikos, E.

AU - Gorman, M.

AU - Barclay, E.

AU - Martin, L.

AU - Jones, A. M.

AU - Saunders, B.

AU - Guenther, T.

AU - Donaldson, A.

AU - Paterson, J.

AU - Frayling, I.

AU - Novelli, M. R.

AU - Phillips, R.

AU - Thomas, H. J W

AU - Silver, A.

AU - Atkin, W.

AU - Tomlinson, I. P M

PY - 2007/8

Y1 - 2007/8

N2 - Hyperplastic Polyposis (HPPS) is a poorly characterized syndrome that increases colorectal cancer (CRC) risk. We aimed to provide a molecular classification of HPPS. We obtained 282 tumours from 32 putative HPPS patients with ≥10 hyperplastic polyps (HPs); some patients also had adenomas and CRCs. We found no good evidence of microsatellite instability (MSI) in our samples. The epithelium of HPs was monoclonal. Somatic BRAF mutations occurred in two-thirds of our patients' HPs, and KRAS2 mutations in 10%; both mutations were more common in younger cases. The respective mutation frequencies in a set of 'sporadic' HPs were 18% and 10%. Importantly, the putative HPPS patients generally fell into two readily defined groups, one set whose polyps had BRAF mutations, and another set whose polyps had KRAS2 mutations. The most plausible explanation for this observation is that there exist different forms of inherited predisposition to HPPS, and that these determine whether polyps follow a BRAF or KRAS2 pathway. Most adenomas and CRCs from our putative HPPS patients had 'classical' morphology and few of these lesions had BRAF or KRAS2 mutations. These findings suggest that tumourigenesis in HPPS does not necessarily follow the 'serrated' pathway. Although current definitions of HPPS are sub-optimal, we suggest that diagnosis could benefit from molecular analysis. Specifically, testing BRAF and KRAS2 mutations, and perhaps MSI, in multiple polyps could help to distinguish HPPS from sporadic HPs. We propose a specific model which would have diagnosed five more of our cases as HPPS compared with the WHO clinical criteria.

AB - Hyperplastic Polyposis (HPPS) is a poorly characterized syndrome that increases colorectal cancer (CRC) risk. We aimed to provide a molecular classification of HPPS. We obtained 282 tumours from 32 putative HPPS patients with ≥10 hyperplastic polyps (HPs); some patients also had adenomas and CRCs. We found no good evidence of microsatellite instability (MSI) in our samples. The epithelium of HPs was monoclonal. Somatic BRAF mutations occurred in two-thirds of our patients' HPs, and KRAS2 mutations in 10%; both mutations were more common in younger cases. The respective mutation frequencies in a set of 'sporadic' HPs were 18% and 10%. Importantly, the putative HPPS patients generally fell into two readily defined groups, one set whose polyps had BRAF mutations, and another set whose polyps had KRAS2 mutations. The most plausible explanation for this observation is that there exist different forms of inherited predisposition to HPPS, and that these determine whether polyps follow a BRAF or KRAS2 pathway. Most adenomas and CRCs from our putative HPPS patients had 'classical' morphology and few of these lesions had BRAF or KRAS2 mutations. These findings suggest that tumourigenesis in HPPS does not necessarily follow the 'serrated' pathway. Although current definitions of HPPS are sub-optimal, we suggest that diagnosis could benefit from molecular analysis. Specifically, testing BRAF and KRAS2 mutations, and perhaps MSI, in multiple polyps could help to distinguish HPPS from sporadic HPs. We propose a specific model which would have diagnosed five more of our cases as HPPS compared with the WHO clinical criteria.

KW - Colorectal tumourigenesis

KW - Genetic pathways

KW - Hyperplastic polyps

UR - http://www.scopus.com/inward/record.url?scp=34547103251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547103251&partnerID=8YFLogxK

U2 - 10.1002/path.2187

DO - 10.1002/path.2187

M3 - Article

C2 - 17503413

AN - SCOPUS:34547103251

VL - 212

SP - 378

EP - 385

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -